GlassScriptPhysician profile
Donald T Brothers
NPI 1609801919
$472.64
in general payments reported to CMS, 2019-2025
9 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.22 · 2022: $29.88 · 2023: $136 · 2024: $130 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382 · Education: $47.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.78 |
| Education | $47.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $123.70 | 2023-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $79.85 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $63.61 | 2024-2025 | Cuvitru, Eohilia |
| Amgen INC. | $48.94 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $45.01 | 2022-2024 | Fasenra |
| Abbvie INC. | $36.98 | 2023 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $35.07 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $20.81 | 2023 | Dupixent |
| Optinose US, INC. | $18.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Brothers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.